Aug 14, 2025 04:39PM Zura Bio (ZURA) Misses Q2 EPS by 17c

Aug 14, 2025 10:22AM Leerink on Zura Bio Ltd. (ZURA): 'We continue to see positive readthrough from NVS' Ph 2 ianalumab'

Jul 18, 2025 06:55AM H.C. Wainwright Reiterates Neutral Rating on Zura Bio Ltd. (ZURA)

Jul 1, 2025 06:30AM Zura Bio (ZURA) Announces CFO Change

May 20, 2025 06:31AM Zura Bio (ZURA) Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 8, 2025 04:42PM Zura Bio (ZURA) Misses Q1 EPS by 19c

Apr 3, 2025 06:47AM Zura Bio Ltd. (ZURA) PT Lowered to $3 at H.C. Wainwright

Mar 26, 2025 07:57AM Zura Bio Ltd. (ZURA) PT Lowered to $10 at Chardan Capital Markets

Mar 25, 2025 04:24PM Guggenheim Reiterates Buy Rating on Zura Bio Ltd. (ZURA)

Mar 25, 2025 12:05PM Leerink Partners Reiterates Outperform Rating on Zura Bio Ltd. (ZURA)

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Dec 24, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Zura Bio Ltd. (ZURA)

Dec 23, 2024 06:44AM Zura Bio (ZURA) Launches Global Phase 2 TibuSURE Study

Nov 14, 2024 04:30PM Zura Bio (ZURA) Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 8, 2024 01:47PM Guggenheim Reiterates Buy Rating on Zura Bio Ltd. (ZURA)

Nov 5, 2024 07:46AM Piper Sandler Reiterates Overweight Rating on Zura Bio Ltd. (ZURA)

Nov 4, 2024 06:20AM Leerink Partners Starts Zura Bio Ltd. (ZURA) at Outperform, 'Multifunctional mAbs, Multiple Ways to Win'

Sep 19, 2024 07:44AM Piper Sandler Reiterates Overweight Rating on Zura Bio Ltd. (ZURA)

Sep 3, 2024 04:53PM Zura Bio (ZURA) Files $300M Mixed Shelf

Aug 14, 2024 05:50AM Chardan Capital Markets Assumes Zura Bio Ltd. (ZURA) at Buy

Jul 12, 2024 06:10AM Zura Bio (ZURA) Commences Warrant Exchange Offer and Consent Solicitation